Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the completion of a multifold oversubscribed $157 million Series C financing round.
The round was led by Sofinnova Partners with substantial participation from a large long-only global asset management company, and participation from additional new investors including a large global sovereign wealth fund, and Avoro Capital Advisors, alongside existing investors RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro Ventures, Maj Invest Equity, and Rock Springs Capital. In connection with this financing, Joe Anderson, PhD, Partner at Sofinnova Partners, will join the Hemab Board.
Read More – Serval Raises $47M in Series A Funding
Advancing Breakthrough Treatments for Glanzmann Thrombasthenia and Factor VII Deficiency
Sutacimig is being developed as the first-ever prophylactic treatment for Glanzmann thrombasthenia (GT), a serious and potentially life-threatening bleeding disorder affecting patients worldwide.
The financing follows the successful completion of sutacimig’s Phase 2 study in GT with planned advancement to a registration study in 2026, alongside expanding into a Phase 2 study in Factor VII deficiency.
“As a mother of two boys with GT, I live with a constant fear, knowing from experience that a simple fall or injury can lead to a life-threatening bleed,” said Alexandra Sullivan, patient advocate and mother. “We feel so limited by the lack of effective treatments in the event of an emergency and cannot stress enough how urgently we feel the need for breakthrough treatments. Our greatest hope is to offer our children a treatment that will allow them to live normal lives. Investment in the development of modern therapies for these underserved patients brings hope to our family.”
Revolutionizing Von Willebrand Disease Treatment
The financing also supports advancing HMB-002 towards a registration study.
HMB-002 is Hemab’s antibody-based treatment with Phase 1 proof of mechanism data showing that it directly targets the underlying pathophysiology of Von Willebrand disease (VWD) by increasing both Von Willebrand Factor and Factor VIII levels. This innovative approach is designed to address the root cause of the bleeding disorder.
“For too long, people living with Von Willebrand Disease have watched from the sidelines as breakthrough prophylactic therapies transformed hemophilia care,” said Jeanette Cesta, Executive Director, VWD Connect Foundation. “HMB-002 represents hope: in its potential to be the kind of innovative, patient-centered treatment our community has been waiting for. It’s time VWD patients had access to the same caliber of medicine that has already changed lives in hemophilia.”
Patients’ Insights Drive Hemab’s Innovation
From inception, Hemab’s program development has been shaped by a portfolio of groundbreaking natural history studies including GT360, FVIID360, and VWD360, which have challenged historical assumptions and uncovered the overlooked burden of these diseases.
Beyond severe, life-threatening bleeds, people face chronic pain, immobility, anxiety, depression, and fatigue – yet only reactive or episodic treatments exist.
Expanding Pipeline and Building the Ultimate Clotting Company
The additional capital enables Hemab to advance additional novel drug candidates into clinical development, with HMB-003 expected to be announced in H1 2026. This expanded pipeline reinforces Hemab’s commitment to developing comprehensive treatment solutions across the spectrum of high unmet need bleeding disorders.
“The quality of our investor syndicate and this significant financing validate our approach and enable us to continue building what we believe will become the ultimate clotting company,” said Benny Sorensen, MD, PhD, CEO of Hemab. “We carefully listen to people living with clotting diseases and collaborate closely with patients and families affected by these conditions to deliver 21st century treatment options. Hemab’s unprecedented deep domain expertise in clotting science, combined with our team’s proven capabilities in advancing programs from early development through approval and commercialization, uniquely positions us to deliver breakthrough therapies. This funding accelerates our mission of transforming lives for people who have waited far too long.”
Investor Perspectives Support Growth Plans
“Hemab’s focus on patients and an innovative approach to treating neglected bleeding disorders, combined with their deep scientific excellence and strong clinical execution, makes it a standout company in the biotech landscape,” said Joe Anderson, PhD, Partner at Sofinnova Partners. “Hemab’s progress across multiple clinical programs gives us confidence in the team’s ability to execute on their ambitious pipeline. We’re excited to support their mission to bring transformative treatments to underserved patient populations with significant medical needs.”
Read More – FieldFlo Receives $35M Growth Investment from Mainsail Partners
